Board of Directors
The Company's Board of Directors is comprised of individuals with public Company and life science industry expertise. The current Board of the Company consists of the following individuals.
Chung-Yu Wang, B.Sc., SIMP Diploma
Cofounder, Chairman of the Board and Director
Mr. Wang is our co-founder and has been Chairman of the board of directors and a director of the Company since its incorporation in April 2004. Mr. Wang has extensive experience in the area of public Company management, international business development and corporate restructure. Mr. Wang currently serves as Chairman of China Coal and Coke Investment Holding Company Limited and Vice Chairman of Tong Lung Metal Industry Co., Ltd. (“Tong Lung Metal”). Mr. Wang was the Chairman of Tong Lung Metal from 2002 to June 2007 and the Chairman of the China Steel Corporation from 1972 to 2001. Mr. Wang also previously served as Chairman of International Iron Institute and the Taiwan Steel and Iron Industries Association.
Mr. Wang received his SIMP Diploma from Harvard University, and Bachelor of Engineering in Chemical from Chung Yuan University, Taiwan. He was also granted an honorary Ph. D. Degree in Chemical Engineering by Chung Yuan University, Taiwan.
Robert DuFresne, MBA
President & CEO & Director
Refer to Management Team for Mr. DuFresne's background.
Alan Moore, Ph.D.
Director
Dr. Moore has been a director of the Company since June 2006. Dr. Moore has 23 years of senior management experience in pharmaceutical research at Procter & Gamble Pharmaceuticals (P&G). At P&G he held several senior positions including General Manager of Cardiac R&D. More recently he was the Executive VP of clinical development and regulatory affairs at Cardiome Pharma Corp. and currently serves as the Director, President and Chief Executive Officer at Stem Cell Therapeutics.
Dr. Moore received his Ph.D. in pharmacology and his Bachelor of Science (Honors) from the Aston University in Birmingham, England.
Hassan Salari, Ph.D.
Director
Dr. Salari has been a director of the Company since October 2004. Dr. Salari has been the Chairman, President and Chief Executive Officer of Chemokine Therapeutics Corporation since July 1998. Dr. Salari is experienced in managing, at both the operational management and director level, private and public biotechnology companies including Inflazyme Pharmaceuticals Ltd. a Toronto Stock Exchange listed Company. Dr. Salari is a former Professor of Medicine at the University of British Columbia, where he assembled several research teams in the fields of autoimmunity and inflammation. He was also a consultant and advisor to pharmaceutical companies in the United States and Europe.
Dr. Salari received his Ph.D. degree from the University of Southampton, United Kingdom, Department of Microbiology, where he focused on the protein chemistry of infectious bacteria. He received his Bachelor of Science from the Tehran University in Iran. Throughout his academic career, Dr. Salari has published over 150 scientific articles and book chapters on various immunology topics and autoimmune diseases. He has previously obtained six U.S. patents for his work on the discovery of novel drugs to treat autoimmune diseases.
Telvin Ju, Ph.D.
Director
Dr. Ju has been a director of the Company since October 2004. Dr. Ju is currently the Senior Vice President of Chinese Maritime Transport Ltd. Chinese Maritime Transport, Ltd. is listed on the Taiwan Stock Exchange. A key part of his role at the Associated Group is to advise and consult for various venture capital and asset management companies on investments in Greater China and Biotechnology. He was previously a research associate at Johns Hopkins University in the Chemistry Department.
Dr. Ju received his Ph.D. degree in Biochemistry from the University of Miami, Florida and his Bachelor of Science in Chemistry and Biology from the University of Miami, Florida.
Michael A. Evans, MBA, CFA, CBV
Director
Mr. Evans has been a director of the Company since March 2005. Mr. Evans is the principal of Evans and Evans, Inc., a financial advisory service company, which he founded in 1989. Previous to that, he worked in the venture capital industry in Western Canada for several years. For the past 17 years Mr. Evans has been responsible for raising funds for numerous clients through private placements, public offerings, and debt issuances. In addition, he has advised on many merger and acquisition transactions and has originated transactions both for purchasers and sellers.
Mr. Evans received his Bachelor of Business Administration degree from Simon Fraser University and Master's degree in Business Administration from the University of Portland, where he graduated with honours. He also holds the professional designation of Chartered Financial Analyst (CFA) and Chartered Business Valuator (CBV). He is a member of the Institute of Chartered Financial Analysts (ICFA) and the Canadian Institute of Chartered Business Valuator (CICBV).
Kevin McGarry, B.Sc., MBA
Director
Mr. McGarry has been a director of the Company since June 2006. Mr. McGarry is currently the Interim Chief Executive Officer of Intelligent Hospital Systems Inc. He is also currently the President of Lombard Life Sciences ("Lombard"), which manages the Western Life Sciences Venture Fund L.P. Western Life Sciences Venture Fund L.P. manages over $43 million of venture capital fund and has a mandate to integrate the science of bio/medical technology companies with the relevant business models. Previous to Lombard, Mr. McGarry was the President of Colliers Pratt McGarry from 1984 to 2001.
Mr. McGarry received his Bachelor of Science and his Master's Degree in Business Administration from the University of Manitoba.